6ftw: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6ftw is ON HOLD  until Paper Publication
+==Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-048==
+<StructureSection load='6ftw' size='340' side='right'caption='[[6ftw]], [[Resolution|resolution]] 2.16&Aring;' scene=''>
-Authors: Singh, A.K., Brown, D.G.
+== Structural highlights ==
+<table><tr><td colspan='2'>[[6ftw]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FTW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FTW FirstGlance]. <br>
-Description: Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-048
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=E6Z:3-{5-[(4aR,8aS)-3-cycloheptyl-4-oxo-3,4,4a,5,8,8a-hexahydrophthalazin-1-yl]-2-methoxyphenyl}prop-2-ynamide'>E6Z</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-[[Category: Unreleased Structures]]
+<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6ftm|6ftm]]</td></tr>
-[[Category: Brown, D.G]]
+<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/3',5'-cyclic-AMP_phosphodiesterase 3',5'-cyclic-AMP phosphodiesterase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.1.4.53 3.1.4.53] </span></td></tr>
-[[Category: Singh, A.K]]
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ftw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ftw OCA], [http://pdbe.org/6ftw PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ftw RCSB], [http://www.ebi.ac.uk/pdbsum/6ftw PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ftw ProSAT]</span></td></tr>
+</table>
+== Disease ==
+[[http://www.uniprot.org/uniprot/PDE4D_HUMAN PDE4D_HUMAN]] Note=Genetic variations in PDE4D might be associated with susceptibility to stroke. PubMed:17006457 states that association with stroke has to be considered with caution.  Defects in PDE4D are the cause of acrodysostosis type 2, with or without hormone resistance (ACRDYS2) [MIM:[http://omim.org/entry/614613 614613]]. ACRDYS2 is a pleiotropic disorder characterized by skeletal, endocrine, and neurological abnormalities. Skeletal features include brachycephaly, midface hypoplasia with a small upturned nose, brachydactyly, and lumbar spinal stenosis. Endocrine abnormalities include hypothyroidism and hypogonadism in males and irregular menses in females. Developmental disability is a common finding but is variable in severity and can be associated with significant behavioral problems.<ref>PMID:22464250</ref>
+== Function ==
+[[http://www.uniprot.org/uniprot/PDE4D_HUMAN PDE4D_HUMAN]] Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.<ref>PMID:15260978</ref> <ref>PMID:15576036</ref>
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: 3',5'-cyclic-AMP phosphodiesterase]]
+[[Category: Large Structures]]
+[[Category: Brown, D G]]
+[[Category: Singh, A K]]
+[[Category: Alternative splicing]]
+[[Category: Camp hydrolysis]]
+[[Category: Hydrolase]]
+[[Category: Phosphodiesterase]]